Hey, happy Wednesday from your trusty Ed Silverman proxy: This edition of Pharmalot is penned by Meghana of Team Readout. Take a healthy break (as I am) from your family’s holiday crazy with some biopharma news:
The clinical trial process of India’s generic drug business is deeply flawed, as a new Reuters report points out. The testing done at Indian clinical research organizations is critical in the approval process of hundreds of medications around the world — but many don’t follow international clinical trial guidelines.
Meanwhile, the battle over insulin market share is heating: Sanofi is suing Novo Nordisk over “misleading” marketing materials. It says Novo’s ads compel doctors and patients to move away from Sanofi’s diabetes drugs, claiming Sanofi’s drugs will be blocked by CVS Caremark next month. Sanofi is seeking damages from Novo Nordisk, and wants it to pull the materials in question, Fierce Pharma writes.
About the Author Reprints
